Drug Profile
Research programme: protocell-based anticancer therapeutics - Seagen
Latest Information Update: 18 Dec 2023
Price :
$50
*
At a glance
- Originator Oncothyreon
- Developer Seagen
- Class Antineoplastics; Drug conjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer